Levaquin and similar antibiotics may be associated with a condition called fluoroquinolone-associated disability, or FQAD. In November 2015, two U.S. Food & Drug Administration (FDA) advisory committees heard testimony from a number of fluoroquinolone patients who developed symptoms that may be associated with FQAD, prompting the members to recommend new warnings for the drug’s labels.
Alleged victims of FQAD may be entitled to compensation for their medical bills, lost wages, pain and suffering, and more. If you would like to learn more about filing a Levaquin FQAD lawsuit, please contact the nationwide law firm of Bernstein Liebhard LLP at (888) 994-5118.
FQAD is the term for a “constellation of symptoms” reported among some patients treated with Levaquin, Cipro, Avelox and other fluoroquinolone antibiotics. These symptoms may include:
Symptoms of the Nervous System
In November 2015, the FDA convened a joint meeting of its Antimicrobial Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee, and asked the members to examine the use of fluoroquinolones in treating acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis in patients with COPD, or uncomplicated urinary tract infections. During the meeting, the FDA advisors heard testimony from patients who had developed FQAD symptoms while using Levaquin and other fluoroquinolones. The Committees ultimately concluded that the current labeling for these drugs was unacceptable, and overwhelmingly endorsed the inclusion of stronger warnings. Read More
The following May, the FDA ordered fluoroquinolone manufacturers to update their products’ boxed warnings, after the agency concluded that the drugs are generally too dangerous for patients with sinusitis, bronchitis and uncomplicated urinary tract infections who have other treatment options. Complications that may be associated with the antibiotics include potentially permanent complications involving the tendons, muscles, joints, nerves and central nervous system that can occur together. Read More
Bernstein Liebhard LLP is investigating legal claims on behalf of individuals who may have developed FQAD related to the use of Levaquin, Cipro or Avelox. Please contact our Firm if you or a loved one were healthy prior to beginning fluoroquinolone therapy, and went on to experience any of the above symptoms for 30 days or longer after treatment ended. To arrange for your free, no-obligation review of your case, please call (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.